Stocks Health care ENLV

NASDAQ · Health care

Enlivex Ltd. (ENLV)

In fiscal 2025 capital spending exceeded operating cash flow by $10.5M. At December 31, 2025 it held $1.9M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 25, 2026.

What Enlivex Ltd. does

Enlivex Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ENLV.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Enlivex Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 25, 2026
   Foreign issuer update 6-K
2. September 22, 2026
   Foreign issuer update 6-K
3. August 17, 2026
   Securities offering prospectus 424B3
4. August 13, 2026
   Passive stake (5% or more) SCHEDULE 13G
5. August 11, 2026
   Foreign issuer update 6-K
6. August 6, 2026
   Form F-3 filing F-3
7. July 30, 2026
   Foreign issuer update 6-K
8. July 29, 2026
   Foreign issuer update 6-K
9. July 28, 2026
   Foreign issuer update 6-K
10. July 28, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 7, the latest on March 18, 2026. Insider transactions on SEC

Who owns ENLV

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Armistice Capital, LLC 4.99% (August 14, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ENLV

What does Enlivex Ltd. do?

Enlivex Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ENLV.

Is Enlivex Ltd. profitable?

Yes. In fiscal 2025 it reported net income of $1.2B.

When did Enlivex Ltd. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 25, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 25, 2026.

Similar companies

Compare ENLV with

Compare ENLV with any company

Follow ENLV

Get an email when Enlivex Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ENLV: get an email when it files

Where the numbers come from

Financial figures are the values Enlivex Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.